Lipase News and Research

RSS

DZD researchers discover additional genetic cause for non-alcoholic fatty liver disease

In Germany about 18 million people suffer from non-alcoholic fatty liver. The causes of this disease are manifold and include environmental as well as genetic factors.

19 May 2020

Kawasaki disease outbreak in children with COVID-19

The ongoing COVID-19 pandemic has marched its way to almost all parts of the world, with hundreds of thousands of deaths and over 4.5 million cases as of May 15, 2020. One saving grace has been the apparent sparing of children, though the mortality in older people is quite high.

17 May 2020

A promising treatment for chronic inflammatory liver disease

Primary sclerosing cholangitis (PSC) is a rare, chronic, inflammatory disease of the bile ducts and is difficult to treat.

14 May 2020

Caffeine may offset some negative health effects of obesogenic diet

A new study in rats suggests that caffeine may offset some of the negative effects of an obesogenic diet by reducing the storage of lipids in fat cells and limiting weight gain and the production of triglycerides.

19 Dec 2019

Study shows unexpected mechanism for lipid acquisition by breast cancer cells

High-fat diets and obesity have been shown to increase the risk of breast cancer and worsen outcomes and prognosis of breast cancer patients. A team of researchers from Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center led by William Kinlaw III, MD, sought to understand how fat from the diet might influence breast cancer cells.

12 Dec 2019

Addressing the evidence behind various therapeutic options for adolescents with obesity

As rates of adolescent obesity continue to rise, choice of treatment needs to be guided by the severity of obesity, psychosocial factors, comorbidities and patient's age and pubertal status, according to a new paper published online in the Journal of the American Medical Association.

30 Sep 2019

FDA approves new drug to treat patients with myelofibrosis

Today, the U.S. Food and Drug Administration approved Inrebic (fedratinib) capsules to treat adult patients with certain types of myelofibrosis.

18 Aug 2019

Researchers test new drug to treat patients with chylomicronemia syndrome

People with familial chylomicronemia syndrome are born with a genetic mutation that means they can't produce an enzyme called lipoprotein lipase.

9 Aug 2019

Study discovers paradoxical proinflammatory effect of endocannabinoids in the brain

A new study led by the Neuropharmacology Laboratory -NeuroPhar at UPF shows that increasing endocannabinoids in the brain may cause inflammation in specific brain areas such as the cerebellum, which is associated with problems of fine motor coordination.

30 Jul 2019

University of Virginia chemist identifies potential addiction-free pain reliever

An estimated 1.7 million Americans suffer from substance abuse disorders related to opioid use for pain relief, according to the National Institute on Drug Abuse.

17 May 2019

The endocannabinoid system and skin conditions

a significant amount of research over the past 20 years has demonstrated that the endocannabinoid system plays a vital role in skin homeostasis, and therefore skin conditions too.

7 May 2019

Study relates DNA methylation levels to obesity

DNA methylation is a mechanism that regulates whether genes are "on" or "off" and is influenced by hereditary and environmental factors, as well as lifestyle and nutritional habits.

10 Apr 2019

Lipid-filled particle plays role in immune function and metabolism

Researchers have discovered that fat tissue releases a lipid-filled particle that has a role in immune function and metabolism. The study, in mice, was published online in the journal Science.

1 Mar 2019

New enzyme biomarker test indicates diseases and bacterial contamination

Researchers at Queen's University Belfast have developed a highly innovative new enzyme biomarker test that has the potential to indicate diseases and bacterial contamination saving time, money and possibly lives.

18 Jan 2019

New therapeutic strategy is emerging for type 2 diabetes

Diabetes is a disease in which blood sugar levels are high over a prolonged period (hyperglycemia). In the case of type 2 diabetes, this phenomenon which is caused by a disruption of the glucose metabolism develops progressively and insidiously.

6 Dec 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated preliminary results from its ongoing Phase 1 clinical study of DCC-2618, the company's broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors as a proffered paper presentation at the European Society of Medical Oncology 2018 Congress in Munich, Germany.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

Lipase News and Research

DZD researchers discover additional genetic cause for non-alcoholic fatty liver disease

Kawasaki disease outbreak in children with COVID-19

A promising treatment for chronic inflammatory liver disease

Caffeine may offset some negative health effects of obesogenic diet

Study shows unexpected mechanism for lipid acquisition by breast cancer cells

Addressing the evidence behind various therapeutic options for adolescents with obesity

FDA approves new drug to treat patients with myelofibrosis

Researchers test new drug to treat patients with chylomicronemia syndrome

Study discovers paradoxical proinflammatory effect of endocannabinoids in the brain

University of Virginia chemist identifies potential addiction-free pain reliever

The endocannabinoid system and skin conditions

Study relates DNA methylation levels to obesity

Lipid-filled particle plays role in immune function and metabolism

New enzyme biomarker test indicates diseases and bacterial contamination

New therapeutic strategy is emerging for type 2 diabetes

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News